MCM2 (Minichromosome Maintenance Complex Component 2) is a critical protein involved in DNA replication and cell cycle regulation. As a member of the MCM family (MCM2-7), it forms a hexameric helicase complex essential for initiating and elongating DNA replication during the S phase. MCM2 binds to replication origins during the G1 phase, licensing them for replication, and unwinds DNA during the S phase in an ATP-dependent manner.
Antibodies targeting MCM2 are widely used in research and diagnostics due to its role as a proliferation marker. Unlike traditional markers (e.g., Ki-67), MCM2 is expressed throughout the cell cycle (G1. S, G2. M phases), making it a sensitive indicator of actively proliferating cells. Its overexpression is linked to uncontrolled cell division in cancers, and MCM2 levels correlate with tumor aggressiveness and poor prognosis.
In clinical settings, MCM2 antibodies are employed in immunohistochemistry (IHC) to assess cell proliferation in cancers (e.g., breast, prostate, and gliomas) and to distinguish between benign and malignant lesions. Additionally, they are used in basic research to study replication mechanisms, checkpoint regulation, and genomic stability. Recent studies also explore MCM2’s potential as a therapeutic target in anticancer strategies.
Overall, MCM2 antibodies serve as valuable tools for understanding DNA replication dynamics and evaluating proliferative activity in both physiological and pathological contexts.